Preventive sublingual immunotherapy with House Dust Mite extract modulates epitope diversity in pre‐school children

The preventive effect of allergen immunotherapy (AIT) on allergy and asthma development is currently assessed using primary and secondary AIT approaches. Knowledge of the immunological effects of these interventions is limited and the impact on epitope diversity remains to be defined.

[1]  A. Sheikh,et al.  EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis , 2018, Allergy.

[2]  P. Demoly,et al.  Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis , 2017, Allergy.

[3]  E. Valovirta,et al.  Results from the 5‐year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy , 2017, The Journal of allergy and clinical immunology.

[4]  M. Neeland,et al.  Primary Prevention of Food Allergy , 2017, Current Allergy and Asthma Reports.

[5]  A. Sheikh,et al.  Allergen immunotherapy for allergic asthma: A systematic review and meta‐analysis , 2017, Allergy.

[6]  A. Plaia,et al.  Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review , 2017, Allergy.

[7]  A. Sheikh,et al.  Allergen immunotherapy for the prevention of allergy: A systematic review and meta‐analysis , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[8]  T. Keil,et al.  Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life , 2017, The Journal of allergy and clinical immunology.

[9]  M. Nielsen,et al.  Linear epitope mapping of peanut allergens demonstrates individualized and persistent antibody-binding patterns. , 2016, The Journal of allergy and clinical immunology.

[10]  G. Roberts,et al.  Effect of Avoidance on Peanut Allergy after Early Peanut Consumption. , 2016, The New England journal of medicine.

[11]  G. Roberts,et al.  Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood. , 2015, The Journal of allergy and clinical immunology.

[12]  O. Lund,et al.  High-throughput sequencing enhanced phage display enables the identification of patient-specific epitope motifs in serum , 2015, Scientific Reports.

[13]  S. Tsui,et al.  The draft genome, transcriptome, and microbiome of Dermatophagoides farinae reveal a broad spectrum of dust mite allergens. , 2015, The Journal of allergy and clinical immunology.

[14]  R. Valenta,et al.  Preventive sublingual immunotherapy in preschool children: First evidence for safety and pro‐tolerogenic effects , 2014, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[15]  Yubao Cui,et al.  Immunoglobulin E-Binding Epitopes of Mite Allergens: From Characterization to Immunotherapy , 2014, Clinical Reviews in Allergy & Immunology.

[16]  Jing Wu,et al.  In Silico Prediction of T and B Cell Epitopes of Der f 25 in Dermatophagoides farinae , 2014, International journal of genomics.

[17]  A. Sheikh,et al.  EAACI Food Allergy and Anaphylaxis Guidelines. Primary prevention of food allergy , 2014, Allergy.

[18]  P. Valent,et al.  Carrier‐bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen‐induced basophil activation in allergic patients , 2012, Allergy.

[19]  A. Boner,et al.  A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay. , 2012, The Journal of allergy and clinical immunology.

[20]  R. Aalberse.  The role of IgG antibodies in allergy and immunotherapy , 2011, Allergy.

[21]  F. Wang,et al.  [Identification of the IgE-binding epitopes in main dust mite allergen Der p 1]. , 2011, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[22]  W. Chuang,et al.  Epitope mapping and structural analysis of the anti-Der p 1 monoclonal antibody: insight into therapeutic potential , 2011, Journal of Molecular Medicine.

[23]  G. Canonica,et al.  Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[24]  B. Sutton,et al.  IgE in allergy and asthma today , 2008, Nature Reviews Immunology.

[25]  H. Sampson,et al.  Peanut epitopes for IgE and IgG4 in peanut-sensitized children in relation to severity of peanut allergy. , 2008, The Journal of allergy and clinical immunology.

[26]  E. Valovirta,et al.  Specific immunotherapy has long‐term preventive effect of seasonal and perennial asthma: 10‐year follow‐up on the PAT study , 2007, Allergy.

[27]  S. Burastero,et al.  Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. , 2004, The Journal of allergy and clinical immunology.

[28]  A. Burks,et al.  Microarray immunoassay: association of clinical history, in vitro IgE function, and heterogeneity of allergenic peanut epitopes. , 2004, The Journal of allergy and clinical immunology.

[29]  R. Merendino,et al.  Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[30]  J. Asturias,et al.  Sequencing and high level expression in Escherichia coli of the tropomyosin allergen (Der p 10) from Dermatophagoides pteronyssinus. , 1998, Biochimica et biophysica acta.

[31]  G. Vergoten,et al.  Specific histamine release capacity of peptides selected from the modelized Der p I protein, a major allergen of Dermatophagoides pteronyssinus. , 1992, Molecular immunology.

[32]  A. Burks,et al.  Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens. , 2013, The Journal of allergy and clinical immunology.